Gene Synthesis: Technologies and Global Markets to Reach $7.2 Billion by 2031

Boston, Oct. 23, 2026 -- The global gene synthesis market is projected to grow from $3.0 billion in 2025 to $7.2 billion by 2031, representing a compound annual growth rate (CAGR) of 16.1% over the 2026–2031 forecast period. This growth trajectory is captured in BCC Research's latest report, Gene Synthesis: Technologies and Global Markets, which positions gene synthesis as one of the most strategically significant segments in life sciences infrastructure.

Key Findings

• The global gene synthesis market is valued at $3.0 billion in 2025 and is forecast to reach $7.2 billion by 2031, at a CAGR of 16.1% (2026–2031). This expansion is primarily driven by surging demand for gene and cell therapies, as pharmaceutical and biotech companies accelerate R&D investment in treatments for rare diseases, cancer, and genetic abnormalities — all of which require scalable, high-precision DNA synthesis.
• North America leads the global market with a 41.0% share, underpinned by a mature biotech ecosystem, substantial government and private R&D funding, and early regulatory approvals for gene therapies that have established a strong commercial foundation for synthesis services.
• Increasing government investment in genomics research is a sustained structural tailwind. Public funding worldwide is directly channeled into DNA synthesis technologies, genome engineering tools, and synthetic biology programs, creating durable and growing demand that insulates the market from short-term commercial volatility.
• The rapid expansion of synthetic biology applications is broadening the addressable market well beyond pharmaceuticals. Industrial biotechnology, agriculture, environmental remediation, and healthcare are all emerging as significant demand centers, diversifying revenue streams for gene synthesis providers and compressing dependence on any single end-use vertical.
• Emerging technologies are reshaping the competitive landscape. Enzymatic DNA synthesis (EDS), chip-based high-throughput DNA synthesis, ligase-based gene synthesis, ultra-long synthetic DNA synthesis (up to 50 kb), and cloud-based bioinformatics platforms are collectively improving synthesis speed, accuracy, and scalability. Integration of machine learning and artificial intelligence into gene design workflows is further reducing synthesis failures, optimizing codon usage, and shortening development timelines.
• The competitive landscape features a mix of established global players and high-growth innovators, including Twist Bioscience, GenScript, Integrated DNA Technologies Inc. (IDT), Thermo Fisher Scientific Inc., Azenta US Inc. (GENEWIZ), Merck KGaA, Eurofins Genomics, Ansa Biotechnologies, Evonetix, DNA TwoPointO Inc. (ATUM), Synbio Technologies, Creative Biogene, OriGene Technologies Inc., ProMab Biotechnologies, and trenzyme GmbH.

Market Drivers

The gene synthesis market is being shaped by intersecting structural forces that reinforce one another across the value chain. Regulatory approvals for gene therapies are translating directly into procurement demand for synthesis services, while declining DNA synthesis and sequencing costs are democratizing access — drawing in smaller biotechnology firms and academic laboratories that were previously priced out of the market. This broadening customer base is amplifying overall market volume and generating new commercial opportunities across geographies.
Simultaneously, AI and machine learning integration is accelerating the design-to-synthesis cycle, enabling providers to reduce error rates, cut production costs, and deliver faster turnaround — competitive advantages that are becoming table stakes in a market where speed and precision are paramount. Ongoing advances in synthesis platforms, including automated workflows and error correction technologies, are further improving throughput and enabling the large-scale synthetic DNA production required for next-generation genomics and synthetic biology initiatives.

Investment Considerations

For investors, the gene synthesis market presents a compelling growth profile anchored in durable demand from gene therapy pipelines, public genomics funding, and the industrial expansion of synthetic biology. Companies with diversified exposure across therapeutic, agricultural, and industrial end markets — and those investing in next-generation synthesis platforms such as EDS and AI-assisted gene design — are best positioned to capture outsized returns. However, investors should weigh risks including regulatory and biosecurity compliance costs, workforce shortages in specialized synthetic biology disciplines, environmental scrutiny of conventional phosphoramidite-based synthesis methods, and revenue sensitivity to fluctuations in research funding and broader biotech investment cycles. Firms with proprietary error-correction technologies and greener synthesis chemistries may command a strategic premium as ESG and quality considerations intensify across the sector.

About the Report

Gene Synthesis: Technologies and Global Markets provides comprehensive market sizing, segmentation, competitive intelligence, and forecasts across the gene synthesis industry for the period through 2031.

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.
For media inquiries, email [email protected] or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.